Ross Law

1 week ago | medicaldevice-network.com | Ross Law

Research estimates that pressure injuries (otherwise known as bedsores) are attributable to approximately 60,000 deaths per year in the US. Research also indicates that with the traditional models for early prevention and care, suffer a higher mortality rate than Caucasian patients, due to the fact that the early warning signs of a developing pressure injury is harder to identify due to their skin tone.

1 week ago | medicaldevice-network.com | Ross Law

RadNet company DeepHealth has signed a $103m deal to acquire iCAD, an AI-powered breast cancer screening company based in New Hampshire, US. The merger agreement’s terms equate to an all-stock buyout of iCAD at approximately $3.61 per share on a fully diluted basis. Subject to customary closing conditions, the transaction is expected to complete by Q3 2025.

1 week ago | hospitalmanagement.net | Ross Law

Research estimates that pressure injuries (otherwise known as bedsores) are attributable to approximately 60,000 deaths per year in the US. Research also indicates that with the traditional models for early prevention and care, suffer a higher mortality rate than Caucasian patients, due to the fact that the early warning signs of a developing pressure injury is harder to identify due to their skin tone.

1 week ago | medicaldevice-network.com | Ross Law

1 week ago | medicaldevice-network.com | Ross Law

The US Food and Drug Administration (FDA) has cleared LUMA Vision’s Verafeye catheter-based imaging system. Verafeye is a four-dimensional (4D), ultrasound-based cardiac visualisation and navigation platform that generates a 360-degree view of the heart. The platform combines the Dublin-headquartered company’s proprietary catheter sensor with advanced digital imaging and deep learning to provide real-time guidance during cardiac surgery.